The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]

from Yahoo Finance https://ift.tt/3dQ9YOz

The coronavirus pandemic showed no signs of relenting on Thursday, with the U.S. marking a new record of over 50,000 cases in a day amid a surge of new cases in the Sun Belt.

from Yahoo Finance https://ift.tt/2D3rhim

Quincy Krosby, Chief market strategist at Prudential Financial, joins The First Trade to discuss her thoughts on the markets and where investors should be looking.

from Yahoo Finance https://ift.tt/3gjXdgz

Those following along with NantKwest, Inc. (NASDAQ:NK) will no doubt be intrigued by the recent purchase of shares by…

from Yahoo Finance https://ift.tt/3imWLQA

Yahoo Finance’s Rick Newman joins The First Trade to discuss Ford’s latest partnership with Disney to unveil its Bronco SUV in July.

from Yahoo Finance https://ift.tt/3ip8azq

from Yahoo Finance https://ift.tt/2Zx3ija

If you are looking for the best ideas for your portfolio you may want to consider some of Amana Mutual Funds top stock picks. Amana Mutual Funds, an investment management firm, is bullish on Intuit Inc (NASDAQ:INTU) stock. In its Q4 2019 investor letter – you can download a copy here – the firm discussed […]

from Yahoo Finance https://ift.tt/3dXs2GB

from Yahoo Finance https://ift.tt/3ioP24v

Amanda Agati, PNC Chief Investment Strategist, joins Yahoo Finance’s Alexis Christoforous, Brian Sozzi and Jared Blikre to discuss the latest market action.

from Yahoo Finance https://ift.tt/2VFccKq

The coronavirus marches on, but healthcare names all over the world are fighting back. Earlier this week, Gilead Sciences (GILD), the manufacturer of COVID-19 antiviral drug remdesivir, revealed the pricing plan for the treatment. A five-day course of remdesivir will be sold to governments of developed nations, including the US, for a price of $2,340 ($390 per vial). US private health insurers will need to fork up $3,120 for the course ($520 per vial). Other countries, though, will find it difficult to get hold of the treatment over the next three months. The Trump administration has purchased over 500,000 doses, which amounts to July’s total production, and 90% of Gilead’s expected output in August and September. Overall, in 2020, Gilead expects to produce up to 3 million courses. Next year, Gilead has set its sights on manufacturing between 600,000 and 800,000 courses a month. The news was greeted with enthusiasm by investment firm Leerink Partners. Firm analyst Geoff Porges increased the revenue forecast for Gilead “by $800 million to $1.8 billion in each of the next three years.” The 4-star analyst expects remdesivir to bring in $1.5 billion of revenue in 2020, rising to $8.5 billion in 2021, and $8.6 billion by 2023. Hopefully, remdesivir’s impact will match that of the 2014 launch of its first HCV medicine, Sovaldi, when GILD’s share price increased by 54% in the three quarters following the launch. Porges said, “We regard the price and its announcement positively, as it establishes a responsible but still profitable benchmark for COVID treatment pricing generally and for Gilead specifically. The strengthened RDV supply together with higher RDV pricing for ex-US markets and stockpiling has significantly increased our forecasts for RDV.” However, Porges tempered expectations by adding, “This forecast still has massive uncertainty given the varying trajectory of the pandemic around the world, the outlook for vaccines, the prospects for alternative and additional medicines, and the appetite of government agencies for stockpiling.” As a result, Porges reiterated an Outperform rating and boosted the price target to $95 (up from $94). Gains of 25% could be heading investors’ way should Porges’ forecast materialize over the coming months. (To watch Porges’ track record, click here) The rest of the Street takes a cautiously optimistic approach to Gilead. A Moderate Buy consensus rating is based on 11 Buys, 12 Holds and 4 Sells. There’s upside of 6%, should the $80.22 average price target be met in the year ahead. (See Gilead stock analysis on TipRanks)

from Yahoo Finance https://ift.tt/2C1qJsA